# 2026-20440: FDA Okays Sound-Wave Tissue Blaster: No Heat, All Zap!

2026-20440, Medical Devices; General and Plastic Surgery Devices; Classification of the Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-10-06; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20440
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20440
- Title: Medical Devices; General and Plastic Surgery Devices; Classification of the Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63493
- Published: 2026-10-06
- Effective: 2026-10-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

FDA Okays Sound-Wave Tissue Blaster: No Heat, All Zap!

## Summary

The FDA is officially classifying the focused ultrasound system for non-thermal, mechanical tissue ablation as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get to patients, boosting innovation and cutting red tape. The new classification is effective October 6, 2026, but has been in effect since October 6, 2023, affecting manufacturers and patients alike.

## Abstract

The Food and Drug Administration (FDA) is classifying the focused ultrasound system for non-thermal, mechanical tissue ablation into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the focused ultrasound system for non-thermal, mechanical tissue ablation. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device moved to Class II (lower hurdle): benefit, medium. The FDA has classified the focused ultrasound system for non-thermal, mechanical tissue ablation as Class II (special controls). This classification became applicable on October 6, 2023 and the order is effective October 6, 2026, and the Agency says this will reduce regulatory burdens and help get…
- Device and future products must use 510(k) pathway: benefit, medium. Because FDA classified this device under the De Novo process, this device type can serve as a predicate so other sponsors may use the less burdensome 510(k) process rather than a De Novo request or premarket approval. The order also states that focused ultrasound systems for non-thermal, mechanical…
- Required special controls impose testing and documentation: cost, medium. To be marketed in this classification, manufacturers must meet special controls including clinical performance testing, animal performance testing, and non-clinical performance testing with specific requirements (for example: acoustic characterization, minimum drive voltages to sustain a bubble clo…
- Labeling must include specific patient safety warnings: benefit, low. Labels must include a warning that focused ultrasound ablation should only be used in patients with sufficient functional reserve to withstand planned tissue destruction, a statement that the device has not been evaluated for treatment of any specific disease or condition, and a detailed summary of…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20440 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20440/medical-devices-general-and-plastic-surgery-devices-classification-of-the-focused-ultrasound-system)
- [2026-20440 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20440.pdf)

## Related
- [Previous: 2026-20435, Reef Fish Fishery of the Gulf of America; Amendment 62](https://policyrisk.com/federal-register/2026-20435)
- [Next: 2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monito…](https://policyrisk.com/federal-register/2026-20441)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20440 (as of 2026-10-13).
